Cite
HARVARD Citation
Beitzen-Heineke, A. et al. (2021). AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. HemaSphere. 5 (9), pp. e630-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Beitzen-Heineke, A. et al. (2021). AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. HemaSphere. 5 (9), pp. e630-. [Online].